FDA Fast-Tracks Eli Lilly Oral GLP-1 Pill (Orforglipron) as Priority Obesity Treatment
The FDA has granted fast-track/priority designation to Eli Lilly's once-weekly oral GLP-1 pill (referred to as 'foundo,' likely orforglipron) for obesity treatment. The speaker frames this as a major shift in access — eliminating the need for injections or refrigeration. No specific efficacy data or trial results are cited in the transcript.